Nrf2 Pathway

Overview

Every cell generates reactive oxygen species (ROS) as a byproduct of normal metabolism — and is exposed to electrophiles from diet, pollution, and drugs. To survive this chemical onslaught, cells deploy a transcription factor called Nrf2 (nuclear factor erythroid 2-related factor 2, gene name NFE2L2) that activates a battery of cytoprotective genes. The Nrf2 system is sometimes called the "master regulator of the antioxidant response," and it is deeply interwoven with mitochondrial function, autophagy, inflammation via NF-κB, and longevity via sirtuins.

For peptide researchers, Nrf2 matters in any study involving oxidative tissue damage — ischemia/reperfusion, neurodegeneration, metabolic disease, wound healing, and skin aging — all of which are also frequent peptide therapeutic targets.

How It Works

The Keap1-Nrf2 Switch

Under basal conditions, Nrf2 is rapidly synthesized but equally rapidly degraded, giving it a half-life of 15-30 minutes. Its guardian is Keap1 (Kelch-like ECH-associated protein 1), a substrate adaptor for the Cul3 E3 ubiquitin ligase complex. Keap1 binds Nrf2 through two motifs (the DLG and ETGE "hinge-and-latch") and presents it for polyubiquitination and proteasomal degradation.

Keap1 itself is a cysteine-rich sensor. When the cell encounters ROS or electrophiles, critical cysteines on Keap1 (Cys151, Cys273, Cys288, and others) are modified. The modification distorts Keap1's conformation so it can no longer hand Nrf2 off to the ubiquitin machinery. Newly synthesized Nrf2 accumulates, translocates to the nucleus, and dimerizes with small Maf proteins at antioxidant response elements (AREs) in target genes.

Downstream Targets

The Nrf2-driven gene network covers five major functional classes:

• Thiol-based antioxidants: glutathione synthesis enzymes (GCLC, GCLM), thioredoxin, peroxiredoxins.
• Phase II detoxification: NQO1, glutathione S-transferases, UGTs.
• Heme and iron metabolism: HMOX1 (heme oxygenase 1), ferritin.
• NADPH generation: G6PD, PGD, ME1, IDH1 — fueling reductive reactions.
• Proteostasis and autophagy: proteasome subunits, autophagy receptor p62/SQSTM1.

Non-Canonical Regulation

Nrf2 is also regulated by GSK3β-β-TrCP-driven degradation (independent of Keap1), by the PI3K/Akt pathway, and by p62-mediated sequestration of Keap1 (the so-called non-canonical activation). These routes become dominant in cancers and metabolic diseases.

Biological Roles

Cytoprotection

Nrf2-null mice are viable but hypersensitive to chemical carcinogens, inflammatory insults, and oxidative injury. Conversely, chronic Nrf2 activation protects neurons, cardiomyocytes, and hepatocytes from a wide array of stressors, including the kind encountered during ischemia-reperfusion.

Metabolic Control

Nrf2 influences lipid metabolism, glucose handling, and mitochondrial biogenesis. It represses lipogenic genes, supports fatty acid oxidation, and protects pancreatic β-cells. The pathway intersects with AMPK and sirtuins in energy sensing.

Inflammation

Nrf2 restrains inflammation by suppressing pro-inflammatory cytokine transcription — partly through direct antagonism of NF-κB target loci and partly by limiting ROS-driven inflammasome activation, overlapping with the biology of pyroptosis and ferroptosis.

Double-Edged Role in Cancer

In premalignant tissue, Nrf2 is tumor-suppressive. Once tumors form, however, somatic mutations in KEAP1 or NFE2L2 (especially in lung adenocarcinoma) produce constitutive Nrf2 activity that fuels proliferation, shields tumors from chemotherapy and radiotherapy, and reprograms metabolism toward serine and glutamine use.

Relevance to Peptides

Peptide angles include:

• Keap1-Nrf2 disruptor peptides: because the Keap1-Nrf2 interaction is a protein-protein interaction with a well-defined ETGE-Kelch binding groove, peptide inhibitors — cyclic peptides and stapled peptides derived from the ETGE motif — have been developed as research tools and preclinical leads.
• Peptides in oxidative tissue diseases: wound-healing peptides, cardioprotective peptides, neuroprotective peptides, and cosmetic antioxidant peptides often converge on Nrf2 as a downstream effector.
• Food- and venom-derived peptides: many dietary peptides (from soy, milk, marine sources) and some venom components activate Nrf2 at nontoxic doses, an area of active nutraceutical research.

Therapeutic Implications

Dimethyl fumarate (Tecfidera) and bardoxolone methyl are clinically relevant Nrf2 activators; both work by modifying Keap1 cysteines. Sulforaphane from broccoli is the prototypical dietary activator. Direct Keap1-Nrf2 protein-protein interaction inhibitors have entered early trials. On the other side, Nrf2 inhibitors for KEAP1-mutant cancers remain an important unmet need.

Current Questions

How to achieve transient, tissue-selective Nrf2 activation without favoring tumor growth; how Nrf2 coordinates with mitochondrial function, autophagy, and apoptosis; and whether peptide-based disruptors can outperform electrophilic small molecules in safety and selectivity, are all active lines of work.